Cargando…

Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis

Pulmonary hypertension is a poor prognostic factor in patients with interstitial lung disease. No established treatment exists for pulmonary hypertension secondary to interstitial pneumonia. We describe the case of an 81-year-old woman with idiopathic pulmonary fibrosis (IPF), who was admitted to ou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Onda, Naomi, Tanaka, Yosuke, Hino, Mitsunori, Gemma, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356039/ https://www.ncbi.nlm.nih.gov/pubmed/26029570 http://dx.doi.org/10.1016/j.rmcr.2014.11.008

Ejemplares similares

Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis—an interim analysis of results from a prospective, single-center, randomized, parallel-group study
por: Tanaka, Yosuke, et al.
Publicado: (2017)

A case of anti-aminoacyl tRNA synthetase (ARS) antibody-positive polymyositis (PM)/dermatomyositis (DM)-associated interstitial pneumonia (IP) successfully controlled with bosentan therapy
por: Naito, Tomoyuki, et al.
Publicado: (2017)

Use of Bosentan in neonatal post cardiac surgery pulmonary hypertension
por: Pawar, Ravindra, et al.
Publicado: (2009)

Bosentan for Treatment of Pediatric Idiopathic Pulmonary Arterial Hypertension: State-of-the-Art
por: Wang, Yuchen, et al.
Publicado: (2019)

Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension
por: Chinello, Pierangelo, et al.
Publicado: (2011)

Review of bosentan in the management of pulmonary arterial hypertension
por: Gabbay, Eli, et al.
Publicado: (2007)

Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
por: Shimomura, Iwao, et al.
Publicado: (2018)

Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
por: Roberts, Kari E, et al.
Publicado: (2009)

Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis
por: Sakao, Seiichiro, et al.
Publicado: (2019)

Transient Use of Oral Bosentan Can Be an Additional Option to Reduce Pulmonary Arterial Hypertension in a Patient with Severe Pulmonary Arterial Hypertension Associated with Atrial Septal Defect
por: Park, Yong Kyu, et al.
Publicado: (2011)

Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient
por: Valerio, Christopher J, et al.
Publicado: (2009)

Cost Effectiveness of Bosentan for Pulmonary Arterial Hypertension: A Systematic Review
por: You, Ruxu, et al.
Publicado: (2018)

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
por: Nosrati, Marzieh, et al.
Publicado: (2020)

A case of nivolumab-induced isolated adrenocorticotropic hormone (ACTH) deficiency
por: Sato, Yozo, et al.
Publicado: (2019)

The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension
por: Karami, Hossein, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension
por: Hakamata, A, et al.
Publicado: (2016)

Acute exacerbation of idiopathic pulmonary fibrosis induced by pertussis: the first case report
por: Hirai, Kuniaki, et al.
Publicado: (2019)

Pulmonary hypertension secondary to interstitial fibrosis with pulmonary venous lesions masquerading pulmonary veno‐occlusive disease
por: Nakayama, Hiroki, et al.
Publicado: (2023)

Beneficial and Adverse Effects of Bosentan Treatment in Korean Patients With Pulmonary Artery Hypertension
por: Sohn, Dae-Won, et al.
Publicado: (2009)

Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension
por: Lee, Young Ho, et al.
Publicado: (2013)

Lower Doses of Bosentan in Combination With Sildenafil Might be Beneficial in Pulmonary Arterial Hypertension
por: Amin, Ahmad, et al.
Publicado: (2015)

Effect of bosentan in pulmonary hypertension development in systemic sclerosis patients with digital ulcers
por: Castellví, Ivan, et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis with bronchogenic carcinoma
por: Nair, Girija, et al.
Publicado: (2009)

Dyspnoea with progressive “idiopathic” pulmonary fibrosis
por: Puri, Chahat, et al.
Publicado: (2021)

Severe progression of idiopathic pulmonary fibrosis post-COVID-19 infection
por: Earl, Naomi, et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis misdiagnosed as sputum-negative pulmonary tuberculosis
por: Isah, Muhammad Danasabe, et al.
Publicado: (2016)

Bosentan, a drug used in the treatment of pulmonary hypertension, can prevent development of osteoporosis
por: Köse, Duygu, et al.
Publicado: (2021)

Sildenafil and Bosentan Plasma Concentrations in a Human Immunodeficiency Virus- Infected Patient with Pulmonary Arterial Hypertension Treated with Ritonavir-Boosted Protease Inhibitor
por: Chinello, Pierangelo, et al.
Publicado: (2015)

Idiopathic hypereosinophilic syndrome with pulmonary hypertension
por: Zhang, Liping, et al.
Publicado: (2018)

A case of malignant catatonia with idiopathic pulmonary arterial hypertension treated by electroconvulsive therapy
por: Hobo, Mizue, et al.
Publicado: (2016)

Idiopathic pulmonary fibrosis and coronary artery disease
por: Cicchitto, Gaetano, et al.
Publicado: (2014)

Combined use of ursodeoxycholic acid and bosentan prevents liver toxicity caused by endothelin receptor antagonist bosentan monotherapy: two case reports
por: Ito, Tomoki, et al.
Publicado: (2014)

Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Gong, Su-Gang, et al.
Publicado: (2018)

Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial
por: Vizza, Carmine Dario, et al.
Publicado: (2017)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
por: Aldalaan, Abdullah M., et al.
Publicado: (2022)

Transition from Bosentan to Ambrisentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study
por: Chen, Jingyuan, et al.
Publicado: (2021)

Monocrotaline-Induced Pulmonary Arterial Hypertension and Bosentan Treatment in Rats: Focus on Plasma and Erythrocyte Parameters
por: Jasenovec, Tomas, et al.
Publicado: (2022)

Broad and heterogeneous vasculopathy in pulmonary fibrosis and emphysema with pulmonary hypertension
por: Sato, Takahiro, et al.
Publicado: (2013)

Idiopathic pulmonary fibrosis associated with pulmonary vein thrombosis: a case report
por: Cavaco, Raquel A, et al.
Publicado: (2009)

Incidence and Clinical Characteristics of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis
por: Yan, Wei, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qg8b7en8gflrll33cjmc3coc45